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in the capacity of individuals to generate FcγRI-, FcγRII- 
and FcγRIII-activating responses were noted. Comparison 
of FcγR-activating IgG with neutralizing and ELISA IgG 
concentrations did not correlate for HCMV and only very 
poorly for MV. Since neither neutralizing IgG nor overall 
IgG responses faithfully predict the activation of FcγRs, 
only the simultaneous quantification of IgGs activating 
defined FcγRs will aid to delineate individual “immuno-
grams” of virus IgG immunity. Such new multiparametric 
assessment of antiviral IgG qualities could be instrumental 
in defining correlates of protection and disease progression.
Keywords Antiviral IgG · FcγRs · ELISA · 
Neutralization · Measles virus · Human cytomegalovirus
Introduction
The exposure to foreign proteins provokes an antigen-
specific adaptive immune response. The humoral arm of 
adaptive immunity is primarily represented by antibodies 
(Abs), and among them, IgG molecules play a particu-
larly important role [1]. The high specificity of IgG for 
its respective antigen allows a retrospective detection of 
previous pathogen encounters. Therefore, it is common 
practice to determine antigen specificity of IgG responses 
for diagnostic purposes or for testing vaccination success. 
Fab–antigen interactions are usually detected by enzyme-
linked immunosorbent assays (ELISA), in which recombi-
nant proteins or protein lysates derived from the respective 
pathogen are coupled on a solid matrix. These methodolo-
gies have undisputable advantages for the rapid identifica-
tion of pathogen-specific IgG. However, in vivo IgGs must 
fulfill various immunological effector functions, some of 
which are Fcγ independent like the recognition of cognate 
Abstract IgG responses are fundamental to adaptive 
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ous pathogen encounter. While specific antigen recognition 
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effector functions become activated via the constant Fcγ 
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humoral immunity to viruses. However, evidence is increas-
ing that antiviral IgG mediates protection to viruses via 
activation of FcγRs. Using a test system allowing quantita-
tive detection of virus-immune IgG able to activate FcγRs, 
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antigen, virus neutralization and opsonization, while oth-
ers include Fcγ-mediated effects like activation of the 
complement cascade, induction of phagocytosis and trig-
gering of distinct FcγRs expressed on a large variety of 
immune cells [1]. Additionally, ELISA-based methodolo-
gies have the disadvantage that viral antigens are often not 
provided in their native conformation and correct mem-
brane topology [2]. The widespread reliance on ELISA-
based tests in clinical virology raises the apparent question 
if and to which extent such data can provide indirect infor-
mation about the IgG quality in terms of defined effector 
functions.
Besides ELISA measurements, levels of virus-specific 
immune IgG are determined by classical in vitro assays 
like immunofluorescence assays, immunoblots, hemagglu-
tination inhibition and virion neutralization tests, but solely 
the latter method provides direct information on a defined 
antiviral effector function that could operate in vivo. The 
antiviral activity of IgGs observed in vivo has been mainly 
attributed to virus neutralization where antibodies inhibit 
virion binding to their entry receptor(s) or prevent fusion 
between viral and host cell membranes. However, many 
epitopes exposed on viral or cellular surfaces are not 
involved in mediating virus entry and fusion and thus do 
not raise neutralizing Ab responses [3–8]. Irrespective of 
its neutralizing capabilities, IgG is biologically relevant by 
eliciting further immune functions (reviewed in Ref. [9]). 
Adoptive transfer experiments provided a proof of principle 
for a prominent role of non-neutralizing IgG in controlling 
primary and recurrent infections, and the absence of detect-
able virion neutralizing activity within protective antiviral 
sera further supports the notion that above-mentioned non-
neutralizing effector functions are crucial to confine repli-
cation of particular viruses, including herpesviruses, MV, 
poxviruses, LCMV and influenza virus [6, 10–15]. Apart 
from that, work from the last few years demonstrated the 
indispensable role of FcγR-mediated effector functions to 
confer IgG immune protection to various viruses in vivo 
including murine herpesvirus-68, HIV and influenza 
[15–20].
FcγRs are exposed on the surface of immune cells. Upon 
recognition of antigen-bound IgG, FcγRs elicit cell type-
specific effector responses such as ADCC, phagocytosis or 
endocytosis of immune complexes to enhance antigen pres-
entation to T lymphocytes [9, 21, 22]. The family of human 
FcγRs is composed of FcγRI (CD64), FcγRIIA, FcγRIIB, 
FcγRIIC (CD32) and FcγRIII (CD16), differing in cellu-
lar distribution, affinities for IgG isotypes [23] and effec-
tor functions elicited upon activation [24]. FcγRI is found 
on monocytes and macrophages and binds monomeric IgG 
with high affinity. FcγRII responds to aggregated IgG and 
exists in three isoforms either transducing activating (IIA, 
C) or inhibitory signals (IIB). FcγRIII is expressed on NK 
cells and macrophages [25] and shows low to medium 
affinity for immune complexes. While neutralizing IgG 
prevents virus entry of cells and is therefore thought to be 
important for establishing “sterilizing” immunity, FcγR-
mediated responses become effective upon production and 
opsonization of viral antigen and thus essential for the con-
trol or progression of subsequent steps of virus spread and 
disease [15, 17, 26–34].
To determine the available fraction of MV- and HCMV-
immune IgG being able to activate defined members of 
the human FcγRs, we applied a set of recently developed 
reporter cells [35]. Briefly, the assays comprise the co-
cultivation of stably transduced FcγR-bearing BW5147 
reporter cells with virus-infected target cells displaying 
native antigens in the presence of IgG. A panel of sera from 
healthy human individuals was analyzed to relate qualities 
and quantities of overall MV and HCMV ELISA-reactive 
IgG to defined antiviral IgG effector functions, e.g., FcγR 
activation and virion neutralization. Extending beyond the 
previously described independence of ELISA and PRNT 
titers [36, 37], only a moderate correlation between global 
IgG amounts and FcγR activation was found in the case 
of MV (a serologically monotypic, vaccine-preventable 
[38] small RNA virus), and no correlation was evident in 
the case of HCMV (a large herpesvirus encoding an exten-
sive antigenic proteome, for which so far no licensed vac-
cine exists [39]), indicating that the FcγR-mediated IgG 
responses cannot be extrapolated from ELISA or plaque 
reduction neutralization test (PRNT) data. The findings 
offer new insights into the functional sub-composition of 
IgG responses against human viruses and highlight the 
unprecedented effector diversity of antiviral IgG in vitro. 
Measuring the FcγR-activating capabilities of antiviral IgG 
increases the prospect to define immune correlates of pro-
tection against infections and/or infection-induced disease 
progression [40].
Materials and methods
Cell lines, viruses and infection conditions
Human MRC-5 lung fibroblasts (ATCC CCL-171) and 
Vero (ATCC CCL-81) cells were maintained in D-MEM 
(Invitrogen Corp, Life Technologies, Darmstadt, Germany) 
supplemented with 10 % (v/v) heat-inactivated fetal calf 
serum (FCS), penicillin (100 U/ml), streptomycin (100 μg/
ml) and glutamine (2 mM). All supplements were from 
Gibco, Life Technologies, Darmstadt, Germany. Mouse 
BW5147 (ATCC TIB-47™) FcγR-ζ reporter cells [35] 
were maintained in RPMI 1640 medium containing 10 % 
(v/v) FCS, penicillin, streptomycin, glutamine and sodium 
pyruvate (1 mM).
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HCMV strain AD169 [41] and the MV strain Edmon-
ston-Enders [42] were used throughout all assays. Infection 
of cells with HCMV and MV was enhanced by centrifu-
gation at 800 g for 30 min. HCMV and MV infection was 
performed at 37 and 32 °C, respectively. If not indicated 
otherwise, cells were infected with 3 PFU/cell to accom-
plish infection of all cells. Virus-specific CPE was moni-
tored by daily microscopic inspection. Co-cultivation with 
BW5147:FcγR-ζ reporter cells was started 72 h post-infec-
tion and continued for 16 h (see below).
Human immunoglobulin preparation and human 
serum samples
A clinically used IVIG preparation, Cytotect® (batch no. 
A158024, Biotest Pharma GmbH, Dreieich, Germany) 
containing ELISA-reactive IgG specific for HCMV and 
MV, was used [43–45]. Cytotect® is manufactured from 
plasma of healthy volunteer donors (4.500–5.000 donors 
per batch) from Germany, Austria, Belgium and USA who 
are selected for high ELISA titers against HCMV. On basis 
of the very broad selection of donors, Cytotect® was used 
as a positive polyclonal control for MV and HCMV-IgG in 
all assays.
Sera of a cohort of 41 donors with unknown immune 
status against MV and HCMV were used for the determi-
nation of individual antiviral IgG response comparisons. 
These sera were kindly donated by healthy volunteers of 
unknown MV vaccination status after written consent. 
Usage of the human sera was approved by the Ethical 
Board of the Medical Faculty of the Heinrich-Heine-Uni-
versity Düsseldorf (file number. 3054/2008). Donors were 
randomly selected, and their age varied from 2 months to 
90 years (see supplementary Table S1). Another cohort of 
18 vaccinees after immunization with MV Triviraten® has 
been described elsewhere [46]. Briefly, 18 sera obtained 
from healthy individuals (age between 13 and 15 years) 
with borderline MV-IgG ELISA reactivity were analyzed 
concerning FcγR-activating IgG and neutralization capabil-
ities. Sera have been collected during the SCARPOL pro-
ject [46, 47] with the approval of the Ethical Board of the 
University of Bern (Switzerland).
IgG and IgM ELISAs and PRNT assays
Detection of global amounts of virus-specific IgG and 
IgM was conducted using ELISA tests from Dade Behring 
(Siemens Healthcare, Erlangen, Germany) [batch no. 
36468 (HCMV-IgM), 36294 (MV-IgG), 36364 (MV-IgM)] 
and from LIAISON DiaSorin (Dietzenbach, Germany) 
(310.740, batch no. 050045/1 [CMV-IgG]). CMV-IgG 
titers were detected by LIAISON, and MV-IgG titers were 
detected by Dade Behring Enzygnost ELISA according to 
the manufacturer’s instructions. The ELISA test systems 
are based on inactivated antigen from cells infected with 
HCMV strain AD169 (www.diasorin.com) or MV strain 
Edmonston, respectively, to a solid phase support.
PRNT assays for MV and HCMV were performed as 
described [48–50]. In brief, MV PRNT was performed by 
preparing serial twofold dilutions of sera or IVIG in mini-
mal essential medium (MEM) alpha medium (Invitrogen, 
Germany) supplemented with 5 % fetal calf serum (FCS). 
Mixtures of MV and sera were prepared by adding a serum 
dilution to an equal volume of an MV suspension con-
taining 40–60 PFU in 100 μl and incubated for 60 min at 
37 °C. Aliquots (100 μl) of these mixtures were transferred 
into cell culture wells with a confluent monolayer of sign-
aling lymphocytic activation molecule (SLAM)-transduced 
CHO cells and incubated at 37 °C for 60 min. The inocu-
lum was removed, and the monolayers were covered with 
an overlay containing 0.5 % carboxymethylcellulose and 
3 % FCS and incubated for 3 days. The monolayers were 
stained with crystal violet and fixed with 3.5 % formalin. 
Plaques were counted visually. For HCMV PRNT, sera and 
IVIG were twofold diluted in minimal essential medium 
(MEM) supplemented with 10 % fetal calf serum (FCS). 
Mixtures of HCMV and sera were prepared by adding a 
serum dilution to an equal volume of an HCMV suspension 
containing 40–60 PFU in 100 µl and incubated for 60 min 
at 37 °C. Aliquots (100 µl) of these mixtures were trans-
ferred into a 90 % confluent monolayer of MRC-5 cells, 
centrifuged for infection enhancement and incubated for 
72 h at 37 °C in a 5 % CO2 atmosphere. Then, the cells 
were fixed with pre-cooled methanol, dried and stained for 
IE HCMV antigens with antibody CCH2 (Dako, Agilent 
Technologies, Germany). Foci were counted visually. The 
HCMV- and MV-specific titer denoted for each serum sam-
ple and for IVIG in PRNT was calculated as the theoretical 
dilution resulting in 50 % reduction of the viral plaque or 
foci number.
Assessing IgG‑dependent activation of the BW:FcγR‑ζ 
reporter cells
The assay used for testing individual IgG-dependent activa-
tion of FcγRs is based on co-cultivation of antigen-bearing 
cells with BW5147 reporter cells stably expressing chi-
meric FcγR-ζ chain receptors which stimulate mouse IL-2 
production in the presence of immune IgG, provided that 
the opsonizing IgG is able to activate the particular FcγR 
[35]. For this purpose, IgG-dependent activation of indi-
vidual BW:FcγR-ζ reporter transfectants was performed by 
incubating mock and virus-infected cells with serial two-
fold dilutions of human sera or IVIG in D-MEM 10 % (v/v) 
FCS for 30 min at 37 °C in an atmosphere of 5 % CO2. 
The range of total IgG concentration used for opsonization 
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varied among viruses (range between 3.5 and 0.0035 mg/
ml). To remove non-immune IgG, cells were washed three 
times with D-MEM containing 10 % (v/v) FCS before co-
cultivation with BW:FcγR-ζ reporter cells for 16 h in RPMI 
10 % (v/v) FCS medium. If not indicated otherwise, experi-
ments were performed in triplicate and the ratio between 
reporter (BW:FcγR-ζ cells) and virus-infected target cell 
was 20:1. After co-cultivation for 16 h at 37 °C in a 5 % 
CO2 atmosphere, supernatants were diluted 1:2 in ELISA 
sample buffer (PBS with 10 % [v/v] FCS and 0.1 % [v/v] 
Tween-20) and mIL-2 was measured by ELISA using the 
capture Ab JES6-1A12 and the biotinylated detection Ab 
JES6-5H4 (BD Pharmingen™, Erembodegem, Belgium).
To compare the principle reactivity of the different 
BW:FcγR-ζ reporter cells, cross-linking experiments were 
performed using grading concentrations of mouse mAbs 
specific for human CD16-A/B (Clone 3G8, BD Pharmin-
gen, Germany), human CD32 (sc-13527, Santa Cruz Bio-
technology, Inc, Heidelberg, Germany) and human CD64 
(Clone 10.1 Ancell Corporation, Minnesota, USA) in com-
bination with GAM IgG Fab2 (Sigma-Aldrich, Seelze, Ger-
many) as a secondary reagent (see supplementary Fig. S1).
To determine individual patterns of IgG-mediated FcγR 
activation, sera were verified regarding the absence of 
MV- and HCMV-specific IgM by ELISA. Only MV and 
HCMV-IgM negative sera were further analyzed. Forty-
one sera obtained from healthy donors were subjected 
to HCMV-IgG ELISA (Liaison, DiaSorin) and MV-IgG 
ELISA (Enzygnost, Dade Behring). Furthermore, PRNT 
and the BW:FcγR-ζ assays using HCMV strain AD169 or 
MV strain Edmonston, respectively, were performed. In the 
BW:FcγR-ζ assays, a serum was regarded as positive, if the 
concentration of secreted IL-2 significantly exceeded the 
response of the respective BW:FcγR-ζ reporter cell toward 
identically infected cells in presence of a serum pool of 
seronegative donors plus three standard deviations (cutoff) 
(see supplementary Fig. S2) [35].
Conceptualization of immunogram and statistical 
analyses
To allow a direct comparison of the individual assays meas-
uring different antiviral IgG activities and conceptualiza-
tion of the “immunogram,” the cutoff results of each serum 
donor in the tests were expressed as percentage of maxi-
mal activation (see supplementary Fig. S2). The sample 
which contained the highest concentration of reactive anti-
bodies was set to 1 (or 100 %). Samples with lower anti-
body reactivities were assigned accordingly with decreas-
ing percentages until reaching 0 (or 0 %), which were the 
negative samples. The results of the relative magnitude of 
responses obtained for IgG ELISA and/or PRNT were used 
as reference to set the order of sera. This arrangement was 
kept (irrespective of the actual responses) when the results 
obtained in other IgG tests are presented. If IgG responses 
obtained in the reference test (ELISA or PRNT) do predict 
FcγR-activating IgG titers, the linear correlation should be 
preserved throughout the other tests when the donors are 
ordered identically. However, if the results from the refer-
ence test are not predictive, the linear correlation should 
vanish. As an indicator for a potential linear relationship 
between the respective response and the reference tests 
(PRNT or ELISA IgG assay, respectively), Pearson’s corre-
lation coefficient (R2), which is an indicator for linear rela-
tionship between measurements, was calculated.
Results
Dissection of MV‑immune IgG
To dissect functional IgG response patterns, we decided 
to begin with a virus producing a restricted array of well-
defined antigenic polypeptides after infection and therefore 
focused on MV. MV represents a serologically monotypic 
small RNA virus which usually produces a self-limiting 
acute systemic infection and a long-lasting IgG memory 
response. Forty-one sera from healthy adult donors were 
randomly selected and analyzed together with the IVIG 
preparation Cytotect® by established detection methods, 
i.e., ELISA for MV-specific IgG (Enzygnost), PRNT, and 
the newly established test panel for IgG-dependent FcγR 
activation [35]. All sera included in the study were tested 
negative for MV-IgM (data not shown), indicating that 
primary infection events date back. Since the BW:FcγR-ζ 
reporter cells vary in their maximal IL-2 production upon 
FcγR engagement, as shown after cross-linking with spe-
cific monoclonal antibodies directed against the ectodo-
main of the respective FcγR (Supplementary Fig. S1 and 
[35]), results were expressed as relative values compared 
to the maximal response. The particular serum sample with 
the strongest reactivity in each of the assay was assigned a 
value of 1 (or 100 %), and the responses of sera exhibiting 
less reactivity were ordered accordingly until reaching 0 %, 
i.e., the value defining a negative result and the absence of 
this functional type of IgG.
Initially, samples were ordered in a decreasing man-
ner according to the reactivity observed in the ELISA IgG 
assay. In Fig. 1a, the relative values of the sera are depicted 
in a bar diagram and the order of samples was set depend-
ing on their relative response achieved in MV-IgG ELISA 
as reference test. This order was kept for the other assay 
formats to assess the predictive value of the reference test 
for FcγR activation. As observed, the linear correlation 
seen in the reference test (R2 = 0.86) vanished when the 
results of other tests were ordered accordingly (Fig. 1a and 
413Med Microbiol Immunol (2016) 205:409–424 
1 3
Supplementary Table S2 for raw values with standard devi-
ations). This indicates that a donor with a high MV-reactive 
ELISA titer is not more likely to have high titers of neutral-
izing or FcγR-activating IgG as well.
The lack of correlation between ELISA and PRNT has 
been previously described [36, 37] and was explained to 
result from the fact that MV surface glycoproteins (H, F) 
contribute less to ELISA reactivity compared to abundant 
structural internal proteins (N, P) [36]. This argument is 
also valid in case of FcγR activation, where only surface-
exposed antigens can trigger FcγR responses. There-
fore, we reordered the samples according to the reactivity 
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Fig. 1  Analysis of measles virus-specific immune IgG reaction pat-
terns of individual human sera. Donor sera were analyzed by the indi-
cated assays for MV-specific IgG responses. The order of the samples 
was set according to the relative magnitude of the response measured 
by ELISA (a) or PRNT (b). For R2 values, see figure. Donor no. 28, 
no. 35 and no. 26 are highlighted by black, white and gray arrows, 
respectively (see text). Bars highlighted by an asterisk were below 
the value defined as positive for that particular assay (see supplemen-
tary Table S2). IVIG, Cytotect®. *Magnitude of relative IgG response 
<0.1
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observed in the PRNT assay (Fig. 1b). This arrangement 
resulted in a lower linear correlation value (R2 = 0.37) due 
to a rather non-homogenous distribution of measurements 
caused by few “super-neutralizers” in our cohort distort-
ing the linearity of the statistical evaluation (donors no. 28, 
24 and 27, Fig. 1B). FcγRIIIA- and FcγRIIA-activating 
MV-immune IgG showed a moderate linear correlation 
(R2 = 0.50 and 0.54, respectively), whereas FcγRIIB-
activating IgG reached only R2 = 0.42. Likewise, the 
linear correlation for FcγRI-activating IgG was also low 
(R2 = 0.21). On the level of individual donors, the MV-spe-
cific IgG profile was quite diverse. For example, donor no. 
35 (Fig. 1a, b, white arrow), who had moderate amounts 
of ELISA-reactive and low neutralizing IgG amounts, 
exhibited strong FcγR-activating IgG titers. Donor no. 28 
(Fig. 1a, b, black arrow) reaching high ELISA reactivity 
and neutralizing capability exhibited only moderate titers 
of FcγRIIIA- and FcγRII- but low FcγRI-reactive IgG 
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Fig. 1  continued
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responses. Donor no. 26 (Fig. 1a, b, gray arrow) showed 
low ELISA reactivity and very few neutralizing IgGs, but 
had moderate titers of FcγR reactive IgG. Taken together, 
the IgG responses measured in the FcγR-ζ activation assays 
followed the linear trend revealed by the global MV-IgG 
detected in the PRNT only to a limited extent as indicated 
by correlation coefficients between 0.21 and 0.54 (Fig. 1a, 
b). The data indicate that the sub-composition of MV-spe-
cific IgG differs considerably among donors with regard 
to the relative concentration of IgG with neutralizing and 
FcγR-activating activities, thus resolving individual MV-
IgG reaction patterns.
Dissection of MV‑immune IgG in serum samples 
of borderline ELISA‑MV‑IgG responses
It has been documented that the magnitude of IgG 
responses to MV differs between individuals with naturally 
acquired immunity versus those having received vaccina-
tion and becomes further modified by booster effects due to 
subsequent MV exposure [51]. As can be concluded from 
their broad age distribution (see Supplementary Table S1), 
donors of the panel investigated for MV-reactive IgG were 
likely to differ with regard to their MV infection or vac-
cination history (e.g., infection by different wildtype MV 
genotypes endemically circulating in Germany which differ 
with regard to certain neutralizing epitopes [50, 52]), sub-
sequent boosting events and other factors; we next analyzed 
a well-characterized separate panel of 18 sera obtained 
from young vaccinees who were selected on the basis to 
contain neutralizing MV antibodies as determined in sensi-
tive PRNT assays but mounted negative, relatively weakly 
positive or only borderline ELISA-MV-IgG responses [46]. 
We hypothesized that these sera containing a higher pro-
portion of MV neutralizing IgG compared to IgG directed 
against internal MV proteins dominating ELISA responses 
should be better suited to uncover a potential correlation of 
NT- and FcγR-activating IgG responses. The PRNT, which 
is the most sensitive detection method for MV-immune IgG 
[53, 54], was used as reference test. The ELISA, PRNT and 
BW:FcγR-ζ reporter cells activation raw values and stand-
ard deviations are all listed in the Supplementary Table 
S3. To compare individual reaction patterns, the sera were 
ordered according to the percentage achieved in the PRNT 
(resulting in a linear correlation of R2 = 0.88 (see Fig. 2)). 
Again, in a number of sera, the titer of MV-ELISA-reactive 
IgG did not correlate with the neutralizing IgG (R2 = 0.05). 
FcγRIIIA-, FcγRIIA-, FcγRIIB- and FcγRI-activating 
MV-immune IgG also failed to show a linear correlation 
with PRNT titers as indicated by R2 = 0.04, 0.02, 0.30 and 
0.04, respectively (see Fig. 2). The data confirmed that the 
sub-composition of the MV-specific IgG responses among 
individuals vaccinated with standard doses of a defined 
attenuated MV vaccine strain is surprisingly heterogene-
ous, and indicate a lack of clear correlation between FcγR 
activation and virion neutralizing IgG responses.
Dissection of effector functions of HCMV‑IgG derived 
from healthy donors
Since we observed discrete albeit only rudimental correla-
tions of functionally defined IgG effector responses against 
MV, we inferred that in case of antigenically more complex 
viruses, like herpesviruses, the different effector subtypes 
of IgG could be even more diverse and less predictable by 
an assessment of ELISA reactivity. To test this assump-
tion, we measured FcγR-ζ responses of individual sera with 
unknown HCMV serostatus. Sera from 41 healthy adult 
donors were analyzed in conjunction with the IVIG prep-
aration Cytotect® by PRNT, ELISA and the novel assays 
measuring HCMV-IgG-mediated activation of FcγRs. The 
ELISA, PRNT and BW:FcγR-ζ reporter cells activation 
raw values and standard deviations are listed in the Supple-
mentary Table S4. All sera were confirmed to be negative 
for HCMV-IgM (data not shown).
To unravel reactivity patterns of individual HCMV-IgG 
donors, the HCMV-IgG ELISA responses were used as ref-
erence to order the sera (Fig. 3a). The IVIG pool yielded 
the maximal response in ELISA, but not in PRNT and 
only half of the BW:FcγR-ζ assays. Interestingly, indi-
vidual HCMV-IgG reaction patterns presented a more pro-
nounced diversity as compared to MV-immune IgG. The 
ordered ELISA data yielded an almost perfect linear trend 
(R2 = 0.94). The ELISA test, which was used, is based on 
the recognition of hypothetically all epitopes of the very 
large array of antigens expressed by HCMV strain AD 169. 
PRNT and ELISA exhibited no correlation as indicated by 
R2 = 0.15, which can be explained by the fact that anti-
body responses neutralizing HCMV particles in human 
fibroblasts are directed to only few HCMV glycoproteins, 
i.e., the gH/gL/gO complex, gB and gM/gN (reviewed 
in Ref. [55]). Likewise, very low R2 values were found 
when ELISA responses were compared with FcγR activa-
tion assessed with opsonized AD169-infected target cells 
(FcγRIIIA R2 = 0.29; FcγRIIA R2 = 0.0001; FcγRIIB 
R2 = 0.022; FcγRI R2 = 0.002), indicating a lack of cor-
relation between these IgG responses.
The antigen display between HCMV particles and the 
plasma membrane proteome of infected target cells is known 
to partially overlap [56, 57]. Accordingly, we next ordered 
the samples pursuant to PRNT values, leading to a moder-
ate linear trend (R2 = 0.60, see Fig. 3b). When this order of 
PRNT reactivity was kept constant, while ELISA and FcγR-
engaging capacities were plotted, the linear trend diminished 
or even vanished (Fig. 3b). For ELISA capabilities, the linear 
correlation dropped to R2 = 0.41, for FcγRIIIA responses 
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to 0.022, and for FcγRI and FcγRIIA/IIB responses to 
R2 = 0.01 and R2 = 0.03, respectively (Fig. 3b). This docu-
ments that neither ELISA nor PRNT titers of anti-CMV IgG 
are predictive for high FcγR-activating potential. This dis-
crepancy was further substantiated on the single donor level. 
For example, donor no. 17 (Fig. 3a, b, black arrow) exhib-
ited high levels of HCMV-IgG reactivity in ELISA contrast-
ing with a very low neutralizing capability and low–medium 
triggering of FcγR responses. Donor no. 44 (Fig. 3a, b, white 
arrow) exhibited intermediate ELISA reactivity, but reached 
highest titers of neutralizing and high concentrations of 
FcγR activation. Donor no. 52 (Fig. 3a, b, gray arrow) exhib-
ited a similar response in ELISA as no. 44, but very low neu-
tralizing IgG, despite high amounts of FcγR-activating IgG. 
This was most pronounced for FcγRI activation. In conclu-
sion, the responses measured in the FcγR-ζ and virion neu-
tralization assays revealed a surprisingly broad heterogeneity 
of personal reaction patterns.
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Fig. 2  Analysis of measles virus-specific immune IgG reaction 
patterns of vaccinees with low to undetectable MV-IgG ELISA 
responses. To compare individual reaction pattern of MV-immune 
IgG generated in response to a defined live attenuated MV vaccine 
strain, Triviraten®, the serum samples were ordered according to the 
magnitude of the PRNT response. For R2 values see figure. The scale 
for the relative magnitude of IgG responses (y axis) for each assay 
was set according to the maximal value (MAX) observed within the 
serum donor panel. This value was compared with the response deter-
mined for IVIG (indicated on the left). Since the relative magnitude 
of IgG response for the assays was so low, an amplification of the 
scale was made. Left panel Scale 0–1. Right panel Scale 0–0.2 maxi-
mal. IVIG, Cytotect®
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Individual IgG effector profiles are not shared 
between MV and HCMV
The observed differences could either be explained by 
genetic traits (e.g., functionally relevant small nucleotide 
polymorphisms (SNPs) in immunoglobulin G heavy chain 
genes or genes involved in IgG N-linked glycosylation) 
or by different histories of infection and antigen exposure 
(e.g., different virus strains or boosting events) and subse-
quent immune reactions. In the first case, one would expect 
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Fig. 3  Analysis of HCMV-immune IgG reaction patterns of indi-
vidual human sera. Donor sera were analyzed by the indicated assays 
for HCMV-specific IgG responses. The order of the samples was 
set according to the relative magnitude of the response measured 
by ELISA (a) or PRNT (b). For R2 values see figure. Donor no. 17, 
no. 44 and no. 52 are highlighted by black, white and gray arrows, 
respectively (see text). Bars highlighted by an asterisk were below 
the value defined as positive for that particular assay (see supplemen-
tary Table S4). IVIG, Cytotect®
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conserved response patterns for different virus infections. 
To this end, we determined whether the individual IgG 
effector pattern against one of the tested viruses (e.g., MV) 
may reflect the IgG effector pattern against the other virus 
investigated (i.e., HCMV). The comparison was carried 
out by analyzing nine sera and the IVIG preparation that 
were found to be reactive in both IgG ELISAs and PRNT 
against MV and HCMV. The results of the serum samples 
were expressed as relative values compared to the maximal 
response, and we ordered the samples according to their 
reactivity displayed in the MV-IgG BW:FcγRIIIA-ζ reporter 
cell activation assay (Fig. 4). Evidently, FcγR-activating 
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Fig. 3  continued
Fig. 4  Comparison of HCMV versus MV-immune IgG reaction pat-
terns of individual human sera. Donor sera were analyzed by the indi-
cated assays for HCMV- and MV-specific IgG responses. The order 
of the samples was set according to the relative magnitude of the 
response measured by the MV-IgG BW:FcγRIIIA-ζ reporter cell acti-
vation assay. IVIG, Cytotect®
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IgG responses to HCMV were generally lower compared to 
MV. Furthermore, no correlation between the IgG effector 
responses against MV and HCMV could be demonstrated. 
We conclude that the IgG effector pattern observed against 
one pathogen does not have predictive value for an antigeni-
cally unrelated viral pathogen.
Discussion
Taking advantage of our recently developed comprehensive 
set of FcγR-ζ chain chimeric reporter cells allowing to detect 
and quantify virus-immune IgG being able to trigger a spe-
cific FcγR (Ref. [34]), we have extensively characterized a 
panel of human sera from healthy donors. This enabled us to 
differentiate and to determine the magnitude of IgG effector 
responses and their potential interrelation with neutralizing 
antibodies. Two widely different human pathogenic viruses 
were selected, specifically the paramyxovirus member MV 
encoding only eight viral proteins, and HCMV, a prototypic 
β-herpesvirus producing the largest known viral proteome 
comprising up to 750 translation products [58]. We restricted 
our analysis of HCMV-IgG responses to the fibroblast-
adapted strain AD169 to ensure consistency with the anti-
gens of the commercial ELISA IgG detection system. The 
analysis of AD169 infection of fibroblasts which is mediated 
by the glycoproteins gH/gL/gO is likely to imply an under-
estimate of the overall neutralizing IgG responses present in 
the sera since HCMV entry of clinical isolates into endothe-
lial and epithelial cells relies primarily on the pentameric 
complex (gH/gL/UL128/UL130/UL131) which is targeted 
by a majority of the neutralizing IgG [59], but could also 
be present on infected cells. The analysis of HCMV strains 
with intact pentamers in our set of assay systems is therefore 
an obvious task in the future. Despite the elimination of this 
additional level of antigenic variability due to the pentamer-
deficient AD169 strain used here in both the PRNT and 
FcγR activation assays, surprisingly, no correlation between 
FcγR-activating and neutralizing IgG responses was noted. 
This was also not the case in a quite homogenous cohort of 
teenage vaccinees upon MV vaccine uptake [46] exhibiting 
only low or no detectable ELISA-MV-IgG responses. The 
latter are thought to be dominated by antibodies recognizing 
internal MV proteins [60], a fact that could possibly impede 
the analysis of IgG effector responses to surface MV glyco-
protein antigens H and F which are targeted by neutralizing 
[61] as well as FcγR-activating IgG.
Why do neutralizing IgG responses hardly correlate 
with FcγR activation by opsonizing IgG?
Several explanations are possible for this unexpected 
finding. The epitopes recognized by neutralizing versus 
FcγR-activating IgG could differ in several aspects, e.g., 
(1) their number on viral entry proteins, (2) their localiza-
tion and (3) the number of IgG ligands that are required to 
mediate one particular response. While defined biochemical 
features of IgG molecules like their N-linked glycan link-
age at Asn297 and the IgG subclass assignment are known 
to be highly crucial for FcγR interaction [9, 23], neutraliza-
tion of virions is determined by the physical interference 
of bound IgG with the concerted structural changes of host 
and viral proteins mediating the viral entry process. Viral 
fusion proteins are central in this sequence of events. On 
the intact virion, the fusion proteins are in a high-energy 
metastable pre-fusion conformation, while during infec-
tion the protein undergoes numerous transitions resulting 
in a more stable lower-energy post-fusion conformation of 
the protein. As deduced from available crystal structures 
[62], the extensive structural rearrangement of involved 
fusion proteins is associated with important alterations in 
the formation and accessibility of epitopes present in the 
pre- versus post-fusion conformation. Therefore, the IgG 
clonotypes recognizing the pre-fusion protein displayed 
on infectious virions and those opsonizing the post-fusion 
protein exhibited on the surface of infected cells will differ. 
The contribution of different IgG clonotypes to neutraliz-
ing versus FcγR-activating responses may contribute to the 
discrepant reaction patterns observed. In many virus infec-
tions, the emergence of IgGs that modify the efficacy of 
neutralizing IgGs as “interfering antibodies” or “enhancing 
antibodies” has been documented [63]. It is obvious that 
those IgGs could contribute to activate FcγRs and thus act 
on the contrary to neutralizing IgG.
The individual pattern observed for the FcγRI-, 
FcγRIIA-, FcγRIIB- and FcγRIIIA-mediated responses 
was less diverse as compared to neutralizing or ELISA IgG 
responses, but still differed substantially. Since IgG sub-
classes and Asn297 glycans have crucial influence on the 
relative capacity of IgG molecules to trigger FcγRs, the 
analysis of the subclass composition and Asn297 glycan 
structures of virus-specific IgGs should allow more insight 
how individual “immunograms” (Fig. 5) are constructed.
Intramolecular IgG interactions and viral inhibitors 
influence FcγR activation
Despite continuous exposure of FcγR-bearing immune 
cells to high titers of serum IgG, these cells become only 
activated upon pathogen encounter. This indicates that 
F(ab′)2-dependent recognition of the cognate antigens must 
instruct molecular changes (e.g., either by local clustering 
or conformation changes within the IgG molecule) which 
are sensed by FcγRs. Consistently, it has been shown that 
the binding of staphylococcal protein A and streptococcal 
protein G to CH1 and CH2–CH3 domains of IgG1 is affected 
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by recognition of the specific antigen [64], challenging the 
traditional view of the F(ab′)2 and Fc domains as structur-
ally and functionally independent modules (reviewed in 
[65]). It is thus tempting to speculate that differences in 
the nature of the epitope–paratope interaction (in terms of 
affinity, avidity and availability) might result in differential 
FcγR activation. As documented before [37, 54, 66], over-
all MV-specific IgG responses as determined by standard 
whole-cell ELISA or proteome microarrays [60] largely 
failed to predict neutralizing IgG effector responses. Here 
we document that this is also found true for FcγRI/II/III-
activating MV-IgG. In this context, it is of interest that 
Kim et al. [67] found that inhibition of MV vaccination by 
maternal IgG seems not to be caused by masking of neutral-
izing epitopes as previously thought. Rather, the inhibition 
of B cell responses by MV-specific IgG occurs via bind-
ing to the inhibitory FcγRIIB, emphasizing the need to dis-
criminate between neutralizing and FcγRIIB-mediated IgG 
effector functions. Despite the great variability of FcγR-
mediated responses observed between serum donors, a con-
sistent discrepancy was noticed between HCMV- and MV-
specific responses. As a clear trend seen within MV and 
HCMV double seropositive donors, MV-infected cells were 
considerably more potent to activate FcγRs when com-
pared with HCMV-infected cells (Fig. 4). This effect can be 
attributed to the expression of HCMV-encoded antagonists 
of FcγR activation, e.g., RL11/gp34 and UL119-118/gp68 
[68–70]. The presence of these counteracting immune-
evasive molecules targeting ADCC responses highlights the 
antiviral potency of FcγR-dependent IgG responses which 
put HCMV under constant immune selection pressure [71].
Striving for a refined diagnosis system of antiviral IgG
Virus-specific IgG constitutes a pillar of immunity, and 
its administration to non-immune individuals can allevi-
ate disease or even prevent virus transmission [44, 72, 73]. 
However, ELISA-based measurements of IgG titers have 
often failed to predict the clinical outcome of particular 
viral infections in humans and to serve as a reliable sur-
rogate marker of immune protection [74–76]. We surmise 
that this could be based on the fact that functionally diverse 
but partially overlapping sub-fractions of IgG molecules 
to a given virus exist (see Fig. 5, “immunogram”) which 
may have unequally distributed impact on virus immune 
control. Accordingly, the measurement of global amounts 
of IgG physically bound to viral antigens as in ELISA test 
formats constitutes only a vague attempt to assess a distinct 
correlate of antiviral immunity. A steadily growing number 
of studies support the notion that FcγR-dependent immu-
nity is crucially involved in antiviral control [6, 10–15] and 
vaccine responses [77] but may be also required for suc-
cessful IgG treatment of tumors [78–80], as well as mediat-
ing anti-inflammatory effects of intravenous IgG [81, 82]. 
Hypothesizing that FcγR-activating IgG responses execute 
a relevant yet still ill-defined immune effector function, we 
set out to investigate (1) the proportion of such antibodies 
among the total amount of polyclonal IgG directed against 
a given virus and (2) the quantitative ratios between the 
definable IgG effector functions within a cohort of healthy 
individuals. Our findings reveal a large variety of individual 
effector profiles for virus-immune IgG rather than homoge-
neous reaction pattern against one particular virus or con-
sistent effector profiles across different pathogens within 
one individual (see Figs. 4, 5).
Future validation of FcγR‑activating IgG responses as a 
correlate of immune protection
Animal models are instrumental to better define distinct 
IgG effector functions as mechanistic correlates of antivi-
ral immunity and protection and thus generate hypotheses 
for clinical situations in humans including the more precise 
assessment of successful vaccine responses [3, 5, 6, 15–17, 
77]. Investigating different inbred mouse strains infected 
with mouse cytomegalovirus (MCMV), we observed 
marked interstrain-dependent differences (“immuno-
grams”) of FcγR-dependent IgG immunity resembling the 
Virus-specific Anbodies
ELISA-reacve IgG Anbodies
IgA, IgM included
FcγRI-acvang 
IgG
FcγRIIA-
acvang IgG
FcγRIII-
acvang IgG
Neutralizing 
IgG
Fig. 5  Sub-composition of the virus-specific antibody response—
conceptualization of an “immunogram.” As part of the total amount 
of serum antibodies recognizing a given virus, the pool of virus-
immune IgG is detectable by ELISA depending on the array of viral 
antigens represented in the test and the biophysical binding proper-
ties of immune IgGs. Within the ELISA-reactive IgG fraction, some 
virus-immune IgG clonotypes possess distinct functional properties, 
i.e., virion neutralization or activation of specific FcγRs (FcγRIIIA/
CD16 and/or FcγRIIA/CD32A and/or FcγRIIB/CD32B and/or 
FcγRI/CD64) upon recognition of viral epitopes. Some IgGs may 
exhibit overlapping functional features. In addition to IgG, some IgA 
and IgM antibodies recognizing virion surface epitopes can be neu-
tralizing
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situation in humans (G. Androsiac, H. Hengel, unpublished 
observation). Assessment of the individual FcγR-activating 
profiles of anti-influenza virus-specific mAbs sharing iden-
tical antigen specificity but differing in their IgG subclass 
assignment correlated surprisingly well with their varying 
protection capacity in lethally influenza virus-infected mice 
lacking specific FcγRs (S. Van den Hoecke, K. Ehrhardt, 
H. Hengel, X. Saelens, unpublished observation). In a 
next step, further animal studies should disclose whether 
this predictive accuracy of FcγR-activating IgG responses 
determined by our assays can be verified in reference to 
polyclonal IgG responses and further viral pathogens.
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